March 2020 PMID 30633660

A Pilot Randomized, Placebo-Controlled Trial of Glycine for Treatment of Schizophrenia and Alcohol Dependence.

Jane Serrita, Elizabeth Ralevski, Gihyun Yoon, Ismene Petrakis

Download social card

Mentions

3
Peak: 1 in Jan 2019
across 2 sources since Jan 2019

Extended reach

2,244
potential audience

Total likes

56

Video views

1,676

Mentions per month

Jan 2019 – Dec 2025

Where it's discussed

  • YouTube2 videos
  • X / Twitter1 posts

AI synopsis

What people are saying

The analysis reveals a general acknowledgment that glycine did not outperform placebo in reducing drinking or improving psychiatric symptoms, with phrases like 'no benefit over placebo' underscoring the findings' neutrality. The tone remains cautious, indicating an understanding of the study's role as an initial step rather than a definitive breakthrough.

AgreementModerate agreement

The discussion reflects a moderate level of agreement with the findings, as posters acknowledge that glycine did not show significant benefits, indicating acceptance of the study's results.

InterestNeutral interest

The overall tone suggests a neutral interest level, focusing on the outcome without expressing strong enthusiasm or skepticism.

EngagementModerate engagement

Posters demonstrate some engagement by discussing the implications of the findings, such as the challenge in finding effective treatments, but do not deeply analyze the methodology or ramifications.

ImpactModerate impact

The consensus appears that the study provides valuable, though not groundbreaking, insight into treatment development, marking a modest impact on ongoing research discussions.

Abstract in brief

  • The study tested whether glycine, an amino acid that affects NMDA receptors in the brain, could help reduce alcohol cravings and improve negative symptoms in people with schizophrenia and alcohol dependence, but found no significant benefits compared to a placebo after 12 weeks.
  • The primary measures included alcohol consumption, craving, schizophrenia symptoms, and cognitive functions like memory and attention, but glycine did not show improvements in any of these areas.
  • Although glycine didn't provide the hoped-for benefits, this is an initial step in exploring new treatments that might target both alcohol dependence and schizophrenia symptoms by acting on brain glutamate systems.]

Top posts

Most liked on X and Bluesky
P
@psychopharmacol · X

Glycine showed no benefit over placebo in the reduction of heavy drinking days or craving for alcohol over a 12-week treatment period. Nor was there an effect on negative symptoms of schizophrenia or on cognitive functioning https://t.co/FL5OOehBjJ

Jan 30, 2019 · 569 followers View post →

All mentions

P
@psychopharmacol · X

Glycine showed no benefit over placebo in the reduction of heavy drinking days or craving for alcohol over a 12-week treatment period. Nor was there an effect on negative symptoms of schizophrenia or on cognitive functioning https://t.co/FL5OOehBjJ

Jan 30, 2019 · 569 followers View post →